Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,011
archived clinical trials in
Postmenopausal Syndrome

A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
349
mi
from
Dallas, TX
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
349
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1410
mi
from
Seattle, WA
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1410
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
604
mi
from
Muscle Shoals, AL
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
604
mi
from
Muscle Shoals, AL
Click here to add this to my saved trials
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1210
mi
from
Fresno, CA
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1210
mi
from
Fresno, CA
Click here to add this to my saved trials
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1168
mi
from
Los Angeles, CA
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1168
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1323
mi
from
Monterey, CA
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1323
mi
from
Monterey, CA
Click here to add this to my saved trials
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
610
mi
from
Chicago, IL
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
610
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated:  12/31/1969
1531
mi
from
Waterville, ME
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated: 12/31/1969
1531
mi
from
Waterville, ME
Click here to add this to my saved trials
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1197
mi
from
East Syracuse, NY
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1197
mi
from
East Syracuse, NY
Click here to add this to my saved trials
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1192
mi
from
Johnson City, NY
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1192
mi
from
Johnson City, NY
Click here to add this to my saved trials
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1051
mi
from
Durham, NC
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1051
mi
from
Durham, NC
Click here to add this to my saved trials
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
635
mi
from
Fargo, ND
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
635
mi
from
Fargo, ND
Click here to add this to my saved trials
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
810
mi
from
Columbus, OH
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
810
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
747
mi
from
Kettering, OH
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
747
mi
from
Kettering, OH
Click here to add this to my saved trials
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
641
mi
from
El Paso, TX
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
641
mi
from
El Paso, TX
Click here to add this to my saved trials
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
569
mi
from
Houston, TX
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
569
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
398
mi
from
Tyler, TX
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
398
mi
from
Tyler, TX
Click here to add this to my saved trials
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated:  12/31/1969
4707
mi
from
Antwerpen,
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated: 12/31/1969
4707
mi
from
Antwerpen,
Click here to add this to my saved trials
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
895
mi
from
Cleveland, OH
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
895
mi
from
Cleveland, OH
Click here to add this to my saved trials
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
833
mi
from
Tucson, AZ
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
833
mi
from
Tucson, AZ
Click here to add this to my saved trials
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1150
mi
from
Laguna Hills, CA
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1150
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1168
mi
from
Los Angeles, CA
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1168
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1278
mi
from
Sacramento, CA
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1278
mi
from
Sacramento, CA
Click here to add this to my saved trials
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1266
mi
from
Santa Maria, CA
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1266
mi
from
Santa Maria, CA
Click here to add this to my saved trials
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1317
mi
from
Walnut Creek, CA
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1317
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
413
mi
from
Lakewood, CO
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
413
mi
from
Lakewood, CO
Click here to add this to my saved trials
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1106
mi
from
Leesburg, FL
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1106
mi
from
Leesburg, FL
Click here to add this to my saved trials
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1098
mi
from
Palm Harbor, FL
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1098
mi
from
Palm Harbor, FL
Click here to add this to my saved trials
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1117
mi
from
Tampa, FL
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1117
mi
from
Tampa, FL
Click here to add this to my saved trials
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
815
mi
from
Gainesville, GA
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
815
mi
from
Gainesville, GA
Click here to add this to my saved trials
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
697
mi
from
New Orleans, LA
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
697
mi
from
New Orleans, LA
Click here to add this to my saved trials
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1123
mi
from
Bethesda, MD
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1123
mi
from
Bethesda, MD
Click here to add this to my saved trials
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
841
mi
from
Detroit, MI
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
841
mi
from
Detroit, MI
Click here to add this to my saved trials
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
523
mi
from
Albuquerque, NM
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
523
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
858
mi
from
Asheville, NC
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
858
mi
from
Asheville, NC
Click here to add this to my saved trials
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
635
mi
from
Fargo, ND
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
635
mi
from
Fargo, ND
Click here to add this to my saved trials
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
726
mi
from
Cincinnati, OH
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
726
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1052
mi
from
Duncansville, PA
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1052
mi
from
Duncansville, PA
Click here to add this to my saved trials
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Denton, TX
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Denton, TX
Click here to add this to my saved trials
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1111
mi
from
Richmond, VA
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1111
mi
from
Richmond, VA
Click here to add this to my saved trials
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
574
mi
from
Madison, WI
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
574
mi
from
Madison, WI
Click here to add this to my saved trials
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1304
mi
from
Plantation, FL
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1304
mi
from
Plantation, FL
Click here to add this to my saved trials
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1444
mi
from
Boston, MA
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1444
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated:  12/31/1969
Research Site
5602
mi
from
Ciudad Autónoma de Buenos Aires,
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated: 12/31/1969
Research Site
5602
mi
from
Ciudad Autónoma de Buenos Aires,
Click here to add this to my saved trials
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated:  12/31/1969
908
mi
from
Mayfield, OH
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated: 12/31/1969
908
mi
from
Mayfield, OH
Click here to add this to my saved trials
Transition From Alendronate to Romosozumab (AMG 785)
An Open-label, Randomized Study to Estimate the Percent Change From Baseline in Lumbar Spine Bone Mineral Density After 3 Months of AMG 785 Administration in Postmenopausal Women With Low Bone Mineral Density Previously Treated With Alendronate
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
3718
mi
from
Honolulu, HI
Transition From Alendronate to Romosozumab (AMG 785)
An Open-label, Randomized Study to Estimate the Percent Change From Baseline in Lumbar Spine Bone Mineral Density After 3 Months of AMG 785 Administration in Postmenopausal Women With Low Bone Mineral Density Previously Treated With Alendronate
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
3718
mi
from
Honolulu, HI
Click here to add this to my saved trials
Transition From Alendronate to Romosozumab (AMG 785)
An Open-label, Randomized Study to Estimate the Percent Change From Baseline in Lumbar Spine Bone Mineral Density After 3 Months of AMG 785 Administration in Postmenopausal Women With Low Bone Mineral Density Previously Treated With Alendronate
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
523
mi
from
Albuquerque, NM
Transition From Alendronate to Romosozumab (AMG 785)
An Open-label, Randomized Study to Estimate the Percent Change From Baseline in Lumbar Spine Bone Mineral Density After 3 Months of AMG 785 Administration in Postmenopausal Women With Low Bone Mineral Density Previously Treated With Alendronate
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
523
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Transition From Alendronate to Romosozumab (AMG 785)
An Open-label, Randomized Study to Estimate the Percent Change From Baseline in Lumbar Spine Bone Mineral Density After 3 Months of AMG 785 Administration in Postmenopausal Women With Low Bone Mineral Density Previously Treated With Alendronate
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
833
mi
from
Tucson, AZ
Transition From Alendronate to Romosozumab (AMG 785)
An Open-label, Randomized Study to Estimate the Percent Change From Baseline in Lumbar Spine Bone Mineral Density After 3 Months of AMG 785 Administration in Postmenopausal Women With Low Bone Mineral Density Previously Treated With Alendronate
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
833
mi
from
Tucson, AZ
Click here to add this to my saved trials
Transition From Alendronate to Romosozumab (AMG 785)
An Open-label, Randomized Study to Estimate the Percent Change From Baseline in Lumbar Spine Bone Mineral Density After 3 Months of AMG 785 Administration in Postmenopausal Women With Low Bone Mineral Density Previously Treated With Alendronate
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1317
mi
from
Walnut Creek, CA
Transition From Alendronate to Romosozumab (AMG 785)
An Open-label, Randomized Study to Estimate the Percent Change From Baseline in Lumbar Spine Bone Mineral Density After 3 Months of AMG 785 Administration in Postmenopausal Women With Low Bone Mineral Density Previously Treated With Alendronate
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1317
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
Transition From Alendronate to Romosozumab (AMG 785)
An Open-label, Randomized Study to Estimate the Percent Change From Baseline in Lumbar Spine Bone Mineral Density After 3 Months of AMG 785 Administration in Postmenopausal Women With Low Bone Mineral Density Previously Treated With Alendronate
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
815
mi
from
Gainesville, GA
Transition From Alendronate to Romosozumab (AMG 785)
An Open-label, Randomized Study to Estimate the Percent Change From Baseline in Lumbar Spine Bone Mineral Density After 3 Months of AMG 785 Administration in Postmenopausal Women With Low Bone Mineral Density Previously Treated With Alendronate
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
815
mi
from
Gainesville, GA
Click here to add this to my saved trials